MIRM

NASDAQ · Biotechnology

Mirum Pharmaceuticals Inc

Mid-Cap Stocks Biotech Stocks Healthcare Stocks

$107.16

+4.23 (+4.11%)

As of May 9, 1:18 AM ET ·

MIRM News1 articles

Mirum Surges on Volixibat Success in PSC Itch Trial, FDA Filing Targeted

Mirum Pharmaceuticals announced volixibat met its primary endpoint in a Phase 2b trial for PSC, reducing itch scores. Shares rose 9%. The company plans a pre-NDA FDA meeting this summer and a U.S. filing in H2 2026.